Op-Ed

America is the world’s most innovative country. Or at least it was. By many measures, that title now belongs to China. The authoritarian powerhouse issued more patents than the United States for the first time in 2019, and it has left us in the dust ever since.

President Biden recently set a goal of slashing cancer death rates by at least 50 percent in the next 25 years — and announced billions of dollars in new research funding to make it a reality. It’s a plan with sky-high ambitions, a real “cancer moonshot,” as the president has branded it.

In their quest to lower drug prices, some US leaders have identified a convenient scapegoat: patents.

On the question of taking action to lower prescription drug prices, progressive lawmakers are of two minds. Some argue that Congress should simply pass legislation to allow the government to set the price for prescription medications. That approach, whether wise on policy grounds or not, at least has the virtue of fidelity to our constitutional

Walter G. Copan Opinion: Removing patent rights to lower drug costs is dangerous precedent The Denver Post